Altium Capital Management LP Travere Therapeutics, Inc. Transaction History

Altium Capital Management LP

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2022 May 16, 2022	SELL	$23.61 - $30.6 $3.33 Million - $4.31 Million	-141,000 Closed	0 $0
Q3 2021 Nov 15, 2021	SELL	$12.98 - $25.03 $382,702 - $737,984	-29,484 Reduced 17.29%	141,000 $4.34 Million
Q2 2021 Aug 13, 2021	SELL	$14.11 - $26.4 $564,400 - $1.06 Million	-40,000 Reduced 19.0%	170,484 $2.49 Million
Q1 2021 May 06, 2021	BUY	$23.37 - $31.77 $3.13 Million - $4.26 Million	134,000 Added 175.2%	210,484 $5.26 Million
Q4 2020 Feb 16, 2021	BUY	$19.17 - $27.87 $1.47 Million - $2.13 Million	76,484 New	76,484 $2.09 Million

193

84.6M

776K

900K

Ticker TVTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 64,173,600
Market Cap $1.12B
Description
Travere Therapeutics, Inc., a biopharmaceutical company, focuses on the identification, development, commercialization, and delivering of therapies for the treatment of rare diseases. Its marketed products include Chenodal, a synthetic oral form of chenodeoxycholic acid for the treatment of radiolucent stones in gallbladders; Cholbam, a cholic a...

Get notified when there are updates to the investment portfolio of Altium Capital Management LP, based on Form 13F filings with the SEC.

Stay updated on Altium Capital Management LP with notifications on news.